What is Qelbree?
Qelbree (viloxazine extended-release) is an FDA-approved non-stimulant medication for treating ADHD in patients aged 6 years and older, including adults, that works primarily as a selective norepinephrine reuptake inhibitor with additional serotonergic activity. 1
Mechanism of Action
Qelbree functions through a dual mechanism that distinguishes it from other ADHD medications:
- Primary action: Selective norepinephrine reuptake inhibition, which increases extracellular norepinephrine and dopamine in the medial prefrontal cortex 1, 2
- Secondary serotonergic effects: Acts as a 5-HT2C receptor agonist and 5-HT2B receptor antagonist 2. Recent PET imaging studies demonstrate that at clinically relevant doses, viloxazine occupies 60-72% of 5-HT2C receptors in the brain, suggesting this serotonergic activity contributes meaningfully to its therapeutic effects 3
This combination classifies viloxazine as a "serotonin-norepinephrine modulating agent" rather than a pure norepinephrine reuptake inhibitor 4.
Clinical Background and Repurposing
Viloxazine has an interesting pharmaceutical history. Originally developed and marketed in Europe during the 1970s as an antidepressant, it was withdrawn from markets in 2002 4. The medication was subsequently repurposed for ADHD treatment based on its favorable mechanism of action and decades of established safety data from its antidepressant use 2.
Efficacy Profile
Meta-analytic evidence demonstrates modest but consistent efficacy:
- Adolescents show a standardized mean difference (Hedges' g) of -0.33 (95% CI -0.50 to -0.16) compared to placebo, with no heterogeneity between studies 5
- Effect sizes are generally smaller than stimulants but comparable to atomoxetine 4, 2
- Optimal dosing appears to follow a bell-shaped curve, with doses of 200-400 mg (or 6-8 mg/kg in children) providing optimal outcomes; doses exceeding 400 mg may not provide additional benefit 6
- Therapeutic effects typically emerge within 4-6 weeks, with response curves tapering off at this timepoint 6
Safety and Tolerability
The most common adverse effects include 1, 5:
- Somnolence (including sedation and lethargy)
- Headache
- Decreased appetite
- Fatigue
- Nausea
- Insomnia
Critical safety warnings 1:
- Black box warning for suicidal ideation: Increased risk of suicidal thoughts or actions, particularly within the first few months of treatment or with dose changes—requires close monitoring
- Increased blood pressure and heart rate monitoring required
- Effects on weight necessitate ongoing monitoring
Discontinuation rates due to adverse effects are low (4.15%), though viloxazine carries a 2.48-fold higher risk of discontinuation compared to placebo 6.
Dosing and Administration
- Once-daily dosing with or without food 1
- Capsules should be swallowed whole, or contents may be sprinkled on applesauce or pudding if swallowing is difficult 1
- Dose adjustment required in severe renal impairment 1
- No dose adjustment needed for hepatic impairment of any severity, as pharmacokinetic studies show minimal impact on drug exposure 7
Clinical Positioning
Qelbree represents a second-line non-stimulant option in the ADHD treatment algorithm 4. Current guidelines recommend stimulants as first-line pharmacotherapy, with non-stimulants like viloxazine reserved for:
- Patients who fail to respond adequately to stimulants
- Those who cannot tolerate stimulant side effects
- Patients with contraindications to stimulants (e.g., comorbid substance use disorders, tic disorders, severe anxiety) 4, 2
- Situations where "around-the-clock" symptom control is needed without the rebound effects seen with short-acting stimulants 4
Drug Interactions
Clinically significant interactions occur through CYP1A2 inhibition 2. Viloxazine is contraindicated with:
- MAOIs (must discontinue MAOIs for 14 days before starting viloxazine) 1
- Alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, or theophylline 1
Key Advantages Over Other Non-Stimulants
- Not a controlled substance, eliminating concerns about abuse potential, dependence, and withdrawal 8
- Minimal elevation of dopamine in the nucleus accumbens compared to stimulants, reducing addiction liability 8
- Once-daily extended-release formulation provides consistent coverage 9
- Relatively rapid onset of action (4-6 weeks) compared to some non-stimulants 9
Important Clinical Caveats
The evidence base for viloxazine remains more limited than for established ADHD medications. Long-term efficacy and safety data beyond the acute trial periods are still needed 2, 5. Head-to-head comparisons with other ADHD medications are lacking, making it difficult to definitively position viloxazine relative to atomoxetine or alpha-2 agonists 2.